A Durham-based health care company startup has raised $2.8 million in a private equity offering, according to a filing Friday with the Securities and Exchange Commission.

Zenomics raised the money from one investor, according to the filing.

According to the North Carolina Biotechnology Center, Zenomics is developing a microneedle transdermal patch technology for diabetes, which is able to sense blood glucose levels and respond with appropriate concentrations of insulin.

Zenomics launched in 2015.

The company’s chief executive officer is Xuejie Wang.

“The patch is covered with more than one hundred micro-scale needles,” Dr. Zhen Gu told Diabetes Daily in an interview. “Each needle contains the glucose-responsive formulations loaded with insulin. They can respond to high glucose level and release insulin correspondingly.”

Gu, the company founder, is part of the faculty for the UNC & NC State Joint Department of Biomedical Engineering.

For eight stories about research involving Zhen at UNC and NCSU, check the links included with this post.